Leukemia Chemoprevention and Therapeutic Potentials: Selected Medicinal Plants with Anti-Leukemic Activities

Izuegbuna, Ogochukwu

doi:10.1080/01635581.2021.1924209

Cited by 5 publications

(9 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combrestatins have been shown to be active against many human cancer cell lines and combrestatin A-4 is the strongest in terms of potency. Their principal action is their interaction with the colchicine binding site of the tubulin b subunit and the disruption of tubulin polymerization into microtubules ( Izuegbuna, 2022 ). CA4 has been shown to be cytotoxic towards some cancer cell lines such as the leukemia cell line, P-388, which is resistant to daunorubicin ( McGown and Fox, 1990 ).…”

Section: Traditional African Medicinal Plants Used In the Management ...mentioning

confidence: 99%

The use of African medicinal plants in cancer management

Gaobotse

Venkataraman²,

Brown³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is the third leading cause of premature death in sub-Saharan Africa. Cervical cancer has the highest number of incidences in sub-Saharan Africa due to high HIV prevalence (70% of global cases) in African countries which is linked to increasing the risk of developing cervical cancer, and the continuous high risk of being infected with Human papillomavirus In 2020, the risk of dying from cancer amongst women was higher in Eastern Africa (11%) than it was in Northern America (7.4%). Plants continue to provide unlimited pharmacological bioactive compounds that are used to manage various illnesses, including cancer. By reviewing the literature, we provide an inventory of African plants with reported anticancer activity and evidence supporting their use in cancer management. In this review, we report 23 plants that have been used for cancer management in Africa, where the anticancer extracts are usually prepared from barks, fruits, leaves, roots, and stems of these plants. Extensive information is reported about the bioactive compounds present in these plants as well as their potential activities against various forms of cancer. However, information on the anticancer properties of other African medicinal plants is insufficient. Therefore, there is a need to isolate and evaluate the anticancer potential of bioactive compounds from other African medicinal plants. Further studies on these plants will allow the elucidation of their anticancer mechanisms of action and allow the identification of phytochemicals that are responsible for their anticancer properties. Overall, this review provides consolidated and extensive information not only on diverse medicinal plants of Africa but on the different types of cancer that these plants are used to manage and the diverse mechanisms and pathways that are involved during cancer alleviation.

show abstract

Section: Traditional African Medicinal Plants Used In the Management ...mentioning

confidence: 99%

The use of African medicinal plants in cancer management

Gaobotse

Venkataraman²,

Brown³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The residue was purified by silica gel chromatography eluted with PE to PE: EA = 1: 1 to give ART-isatin hybrids 6a-i. To a solution of ART-isatin hybrids 6a-i 4.2.9 (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9trimethyldecahydro-12H-3,12-epoxy [1,2] dioxepino [4,3-i] 4.2.12 (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9trimethyldecahydro-12H-3,12-epoxy [1,2]dioxepino [4,3-i]isochromen-10-yl 3-(5-methoxy-3-(ethoxyimino)-2-oxoindolin-1-yl)propanoate (7l) 1 H NMR (600 MHz, CDCl 3 ) d 0.72-0.96 (m, 7H), 1.20-1.42 (m, 10H), 1.52-1.56 (m, 1H), 1.63-1.70 (m, 2H), 1.80-1.84 (m, 1H), 1.94-1.98 (m, 1H), 2.23-2.33 (m, 1H), 2.46-2.48 (m, 1H), 2.68-2.76 (m, 2H), 3.74 (s, 3H, OMe), 3.89-4.03 (m, 2H), 4.48 (q, J = 8.0 Hz, 2H), 5.36 (s, 1H), 5.70 (d, J = 4.0 Hz, 1H), 6.78-6.80 (m, 1H), 6.86-6.88 (m, 1H), 7.51-7.54 (m, 1H). 13…”

Section: Synthesismentioning

confidence: 99%

“…3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9trimethyldecahydro-12H-3,12-epoxy[1,2] dioxepino[4,3-i]isochromen-10-yl 2-(5-fluoro-3-(methoxyimino)-2-oxoindolin-1-yl)acetate (7c)NMR (600 MHz, CDCl 3 ) d 0.72-0.92 (m, 7H), 1.09-1.42 (m, 7H), 1.47-1.64 (m, 3H), 1.74-1.78 (m, 1H), 1.89-1.92 (m, 1H), 2.14-2.19 (m, 1H), 2.31-2.34 (m, 1H), 4.16 (s, 3H, NOMe), 4.56-4.64 (m, 2H), 5.41 (s, 1H), 5.66 (d, J = 8.0 Hz, 1H), 6.96-6.99 (m, 1H), 7.12-7.16 (m, 1H), 7.62-7.64 (m, 1H). HRMS-ESI: m/z Calcd for C 26 H 31 FN 2 O 8 Na [M+Na] + : 541.1957; Found: 541.1916.4.2.4 (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9trimethyldecahydro-12H-3,12-epoxy[1,2] dioxepino[4,3-i]isochromen-10-yl 2-(5-fluoro-3-(methoxyimino)-2-oxoindolin-1-yl)acetate (7d) NMR (600 MHz, CDCl 3 ) d 0.78-0.96 (m, 7H), 1.19-1.41 (m, 7H), 1.54-1.57 (m, 1H), 1.63-1.71 (m, 2H), 1.81-1.83 (m, 1H), 1.94-1.98 (m, 1H), 2.28-2.34 (m, 1H), 2.49-2.53 (m, 1H), 3.74 (s, 3H, OMe), 4.25 (s, 3H, NOMe), 4.36 (d, J = 12.0 Hz, 1H), 4.62 (d, J = 12.0 Hz, 1H), 5.36 (s, 1H), 5.74 (d, J = 8.0 Hz, 1H), 6.60 (d, J = 4.0 Hz, 1H), 6.84 (dd, J = 4.0, 2.0 Hz, 1H), 7.52 (d, J = 2.0 Hz, 1H…”

mentioning

confidence: 99%

“…3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl 3-(3-(methoxyimino)-2oxoindolin-1-yl)propanoate (7e) NMR (600 MHz, CDCl 3 ) d 0.70-0.96 (m, 7H), 1.19-1.30 (m, 3H), 1.36-1.45 (m, 4H), 1.52-1.55 (m, 1H), 1.63-1.69 (m, 2H), 1.80-1.83…”

mentioning

confidence: 99%

“…10 (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9trimethyldecahydro-12H-3,12-epoxy[1,2] dioxepino[4,3-i]isochromen-10-yl 3-(3-[(benzyloxy)imino)-5-fluoro-2-oxoindolin-1-yl] propanoate (7j) NMR (600 MHz, CDCl 3 ) d 0.71-0.97 (m, 7H), 1.20-1.29 (m, 3H), 1.36-1.42 (m, 4H), 1.53-1.56 (m, 1H), 1.63-1.67 (m, 2H), 1.81-1.83 (m, 1H), 1.94-1.98 (m, 1H), 2.28-2.33 (m, 1H), 2.46-2.48 (m, 2H), 3.92-4.01 (m, 2H), 5.35 (s, 1H), 5.44 (s, 2H), 5.68 (d, J = 4.0 Hz, 1H), 6.86 (dd, J = 4.0, 2.0 Hz, 1H), 7.04 (td, J = 8.0, 2.0 Hz, 1H), 7.29-7.34 (m, 3H), 7.37-7.39 (m, 2H), 7.58 (dd, J = 8.0, 2.0 Hz, 1H…”

mentioning

confidence: 99%

See 2 more Smart Citations

Development and evaluation of novel artemisinin-isatin hybrids with potential anti-leukemic cytotoxicity

et al. 2023

View full text Add to dashboard Cite

Twenty-one novel ester tethered artemisinin-isatin hybrids were designed, synthesized and screened against human myeloid leukemia cell lines (K562 and K562/ADR), human acute lymphoblastic leukemia cell line (CCRF-CEM) as well as normal human peripheral blood mononuclear cells (PBMCs) for their cytotoxicity by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The structure-activity relationships (SARs) were also discussed to facilitate further rational design of more effective candidates. The preliminary results showed that most of the ester tethered artemisinin-isatin hybrids (IC50: 0.32-29.35 µM) exhibited promising activity against CCRF-CEM cells, and some of them (IC50: 1.23-49.84 µM) were also active against K562 and K562/ADR human myeloid leukemia cell lines. Among them, hybrid 7d (IC50: 0.32, 2.67 and 1.23 µM) not only possessed profound activity against the three tested leukemia cell lines and excellent safety and selectivity profiles, but also showed promising pharmacokinetic properties. Accordingly, hybrid 7d could be considered as a potential lead molecule for the development of novel anti-leukemic agents with minimal untoward events to normal human cells.

show abstract